Truist Financial Reaffirms Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Truist Financial reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZFree Report) in a research note released on Wednesday morning, Benzinga reports. Truist Financial currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

A number of other equities analysts also recently commented on JAZZ. JPMorgan Chase & Co. reduced their price objective on shares of Jazz Pharmaceuticals from $180.00 to $170.00 and set an overweight rating for the company in a report on Thursday, February 29th. Piper Sandler lifted their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an overweight rating in a report on Wednesday. Stifel Nicolaus lifted their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a buy rating in a report on Friday, March 15th. StockNews.com raised shares of Jazz Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, January 30th. Finally, Needham & Company LLC restated a buy rating and issued a $220.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus price target of $193.42.

View Our Latest Stock Report on JAZZ

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $121.81 on Wednesday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of 19.90, a P/E/G ratio of 1.72 and a beta of 0.59. The company’s fifty day moving average is $122.52 and its two-hundred day moving average is $125.04. Jazz Pharmaceuticals has a 52-week low of $111.25 and a 52-week high of $147.98.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. Equities research analysts forecast that Jazz Pharmaceuticals will post 16.3 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip L. Johnson acquired 12,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of JAZZ. Vestal Point Capital LP bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $89,175,000. Envestnet Asset Management Inc. lifted its stake in Jazz Pharmaceuticals by 900.5% in the first quarter. Envestnet Asset Management Inc. now owns 514,654 shares of the specialty pharmaceutical company’s stock valued at $6,364,000 after buying an additional 463,213 shares in the last quarter. Armistice Capital LLC lifted its stake in Jazz Pharmaceuticals by 108.4% in the fourth quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock valued at $80,150,000 after buying an additional 338,882 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in Jazz Pharmaceuticals by 558.6% in the third quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after buying an additional 273,764 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 28.1% in the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after buying an additional 224,865 shares in the last quarter. Institutional investors own 88.15% of the company’s stock.

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Read More

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.